

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number  
**WO 2005/012524 A1**

- (51) International Patent Classification<sup>7</sup>: C12N 15/11, A61K 38/00
- (21) International Application Number: PCT/GB2004/003235
- (22) International Filing Date: 23 July 2004 (23.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0317466.1 25 July 2003 (25.07.2003) GB
- (71) Applicant (for all designated States except US): **THE UNIVERSITY OF SHEFFIELD [GB/GB]**; Western Bank, Sheffield S10 2TN (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **HELLEDAY, Thomas** [SE/SE]; Erik Dahlbergsgatan 38, S-115 32 Stockholm (SE).
- (74) Agent: **HARRISON GODDARD FOOTE**; 31 St. Saviourgate, York YO1 8NQ (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/012524 A1

(54) Title: USE OF RNAI INHIBITING PARP ACTIVITIY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

USE OF RNAI INHIBITING PARP ACTIVTIY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE  
TREATMENT OF CANCER

This invention relates to the use of an agent that inhibits the activity of an enzyme which mediates the repair of DNA strand breaks in the treatment of certain forms of  
5 cancer in particular breast cancer.

Homologous recombination (HR) has been shown to play an important role in repair of damage occurring at DNA replication forks in mammalian cells (2). Thus, cells deficient in HR show retarded growth and exhibit higher level of genetic instability. It  
10 is believed that genetic instability due to loss of HR repair in human cancers significantly contributes to the development of cancer in these cells (1).

Post transcriptional modification of nuclear proteins by poly(ADP-ribosylation) (PARP) in response to DNA strand breaks plays an important role in DNA repair,  
15 regulation of apoptosis, and maintenance of genomic stability.

Poly(ADP-ribose) Polymerase (PARP-1) is an abundant nuclear protein in mammalian cells that catalyses the formation of poly(ADP-ribose) (PAR) polymers using NAD<sup>+</sup> as substrate. Upon DNA damage, PARP-1 binds rapidly to a DNA  
20 strand break (single strand or double strand) and catalyses the addition of negatively charged PAR chains to itself (automodification) and other proteins (see [3, 4] for reviews). The binding of PARP-1 to DNA strand breaks is believed to protect DNA lesions from further processing until PARP-1 is dissociated from the break by the accumulated negative charge resulting from PAR polymers (5,6).

25 Although PARP-1 has been implicated in several nuclear processes, such as modulation of chromatin structure, DNA replication, DNA repair and transcription, PARP-1 knockout mice develop normally (7). Cells isolated from these mice exhibit a hyper recombination phenotype and genetic instability in the form of increased levels of SCE, micronuclei and tetraploidy (8-10). Genetic instability may also occur  
30 in these PARP-1 knockout mice through telomere shortening, increased frequency of chromosome fusion and aneuploidy (11), although all of these results could not be repeated in another set of PARP-1 knock-out mice (12). In the former mice knockout, PARP-1 null mutation rescue impaired V(D)J recombination in SCID mice (13).

- These results support the view suggested by Lindahl and coworkers that PARP-1 has a protective role against recombination (5). They proposed that binding of PARP-1 to DNA strand breaks prevents the recombination machinery from recognizing and processing DNA lesions or, alternatively, that the negative charges accumulated following poly ADP-ribosylation repel adjacent recombinogenic DNA sequences. Only the latter model is consistent with inhibition of PARP-1 itself and expression of a dominant negative mutant PARP-1, inducing SCE, gene amplification and homologous recombination (HR [14-18]).
- Studies based on treating cells with PARP inhibitors or cells derived from PARP-1 or PARP-2 knockout mice indicate that the suppression of PARP-1 activity increases cell susceptibility to DNA damaging agents and inhibits strand break rejoicing (3, 4, 8-11, 19, 20, 47).
- Inhibitors of PARP-1 activity have been used in combination with traditional anti-cancer agents such as radio therapy and chemotherapy (21). The inhibitors were used in combination with methylating agents, topoisomerase poisons and ionising radiations and were found to enhance the effectiveness of these forms of treatment. Such treatments, however, are known to cause damage and death to non cancerous or “healthy” cells and are associated with unpleasant side effects.

There is therefore a need for a treatment for cancer that is both effective and selective in the killing of cancer cells and which does not need to be administered in combination with radio or chemotherapy treatments.

- The present inventors have surprisingly found that cells deficient in homologous recombination (HR) are hypersensitive to PARP inhibitors as compared to wild type cells. This is surprising since PARP-1 knockout mice live normally thereby indicating that PARP-1 is not essential for life. Thus, it could not be expected that cells would be sensitive to PARP inhibition.

According to a first aspect of the invention there is provided the use of an agent that inhibits the activity of an enzyme that mediates the repair of DNA strand breaks in the

manufacture of a medicament for the treatment of diseases that are caused by a genetic defect in a gene that mediates homologous recombination.

In a further aspect the invention provides a method of treatment of a disease or  
5 condition in a mammal, including human, which is caused by a genetic defect in a gene which mediates homologous recombination, which method comprises administering to the mammal a therapeutically effective amount of an agent which inhibits the activity of an enzyme which mediates repair of DNA strand breaks or other lesions present at replication forks.

10

In a preferred aspect said enzyme is PARP. In a further preferred aspect said agent is a PARP inhibitor or an RNAi molecule specific to PARP gene.

In a further preferred aspect, the use is in the treatment of cancer.

15

Preferably the medicament is a pharmaceutical composition consisting of the PARP inhibitor in combination with a pharmaceutically acceptable carrier or diluent.

The specific sensitivity of HR defective tumours to PARP-1 inhibition means that  
20 normally dividing cells in the patient will be unaffected by the treatment. Treatment of HR defective cancer cells using a PARP inhibitor also has the advantage that it does not need to be administered as a combination therapy along with conventional radio or chemotherapy treatments thereby avoiding the side effects associated with these conventional forms of treatment.

25

A genetic defect in a gene which mediates homologous recombination may be due to a mutation in, the absence of, or defective expression of, a gene encoding a protein involved in HR.

30 In a further aspect, the invention further provides the use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.

In another aspect the invention provides a method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor.

- 5 By causing apoptosis in HR defective cells it should be possible to reduce or halt the growth of a tumour in the mammal.

Preferably, the HR defective cells are cancer cells.

- 10 Cancer cells defective in HR may partially or totally deficient in HR. Preferably the cancer cells are totally deficient in HR.

The term "cancer" or "tumour" includes lung, colon, pancreatic, gastric, ovarian, cervical, breast or prostate cancer. The cancer may also include skin, renal, liver, 15 bladder or cerebral cancer. In a preferred aspect, the cancer is in a mammal, preferably human.

- 20 The cancer to be treated may be an inherited form of cancer wherein the patient to be treated has a familial predisposition to the cancer. Preferably, the cancer to be treated is gene-linked hereditary cancer. In a preferred embodiment of the invention the cancer is gene-linked hereditary breast cancer.

- In a preferred aspect, the PARP inhibitor is useful in the treatment of cancer cells defective in the expression of a gene involved in HR. Genes with suggested function in 25 HR include XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, 30 FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Eme1, DDS1, BARD (see (2, 3, 5, 22-28) for reviews).

A gene involved in HR may be a tumour suppressor gene. The invention thus provides for the treatment of cancer cells defective in the expression of a tumour suppressor gene. Preferably, the tumour suppressor gene is BRCA1 or BRCA2.

Breast cancer is the most common cancer disease among women in the Western world today. Certain families have strong predisposition for breast cancer, which is often owing to an inherited mutation in one allele of either BRCA1 or BRCA2. However, 5 these patients still maintain one functional allele. Thus, these patients develop normally and have no phenotypic consequence from this mutation. However, in one cell, the functional allele might be lost, making this cell cancerous and at the same time deficient in homologous recombination (HR). This step is critical for the onset of a tumour (1).

10

The present inventors have surprisingly found that BRCA2 deficient cells are 100 times more sensitive to the cytotoxicity of the PARP inhibitor, NU1025, than wild type cells.

15 Thus in a preferred aspect, the invention provides the use of a PARP inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in HR, e.g due to the loss of BRCA1 and/or BRCA2 expression.

20 The cancer cells to be treated may be partially or totally deficient in BRCA1 or BRCA2 expression. BRCA1 and BRCA2 mutations can be identified using multiplex PCR techniques, array techniques (29, 30) or using other screens known to the skilled person.

PARP inhibitors useful in the present invention may be selected from inhibitors of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 or tankyrase 2 (see 31 for a review).

25 In a preferred embodiment, the PARP inhibitor useful in the present invention is an inhibitor of PARP-1 activity.

PARP inhibitors useful in the present invention include benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline derivatives (e.g.2-(4-hydroxyphenyl)benzimidazole-4-carboxamide (NU1085), 8-hydroxy-2-methylquinazolin-4-[3H]one (NU1025); 6(5H)phenanthridinone; 3 aminobenzamide; benzimidazole-4-carboxamides (BZ1-6) and tricyclic lactam indoles (TI1-5) [32]. Further inhibitors of PARP may be identified either by design [33] or the novel FlashPlate assay [34].

The PARP inhibitor formulated as a pharmaceutical composition may be administered in any effective, convenient manner effective for targeting cancer cells including, for instance, administration by oral, intravenous, intramuscular, intradermal, intranasal, 5 topical routes among others. Carriers or diluents useful in the pharmaceutical composition may include, but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.

In therapy or as a prophylactic, the active agent may be administered to an individual 10 as an injectable composition, for example as a sterile aqueous dispersion. The inhibitor may be administered directly to a tumour or may be targeted to the tumour via systemic administration.

A therapeutically effective amount of the inhibitor is typically one which is sufficient 15 to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the inhibitor. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.

20 For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be up to 100mg/kg, for example from 0.01mg/kg to 50 mg/kg body weight, typically up to 0.1, 0.5, 1.0, 2.0 5.0, 10, 15, 20 or 30mg/kg body weight. Ultimately, however, the amount of inhibitor administered and the frequency of administration will be at the discretion of a physician.

25 A therapeutic advantage of using PARP inhibitors to treat cancer cells is that only very low doses are needed to have a therapeutic effect in treating cancer thereby reducing systemic build up of the inhibitors and any associated toxic effects.

30 A preferred aspect of the invention provides an agent which is an inhibitory RNA (RNAi) molecule.

A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in

the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.

5 Preferably said RNAi molecule is derived from the nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- a) a nucleic acid sequence as represented by the sequence in Figure 9, 10, 11, 10 12, 13 or 14 or fragment thereof;
- b) a nucleic acid sequence which hybridises to the nucleic acid sequences of Figure 9, 10, 11, 12, 13 or 14 and encodes a gene for PARP;
- c) a nucleic acid sequence which comprise sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a) 15 and (b).

Recent studies suggest that RNAi molecules ranging from 100-1000bp derived from 20 coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

More preferably said RNAi molecule according has a length of between 10 nucleotide 25 bases (nb) –1000nb. Even more preferably said RNAi molecule has a length of 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb; or 100bp. Even more preferably still said RNAi molecule is 21nb in length.

Even more preferably still the RNAi molecule comprises the nucleic acid sequence 30  
aaa agc cau ggu gga gua uga (PARP-1)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence  
aag acc aau cuc ucc agu uca ac (PARP-2)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence  
aag acc aac auc gag aac aac (PARP-3)

The RNAi molecule may comprise modified nucleotide bases.

5

Preferred features of each aspect of the invention are as for each of the other aspects  
*mutatis mutandis*.

The present invention will now be described by way of example only with reference

10 to the accompanying figures, wherein:

Figure 1 is a graph demonstrating that HR deficient cells are hypersensitive to the toxic effect caused by inhibition of PARP-1. Colony outgrowth of the Chinese hamster cell lines AA8 (wild-type), irs1SF (deficient in HR[4]), CXR3 (irs1SF 15 complemented with XRCC3 [2]), V79 (wild-type), irs1 (deficient in HR[5]) or irs1X2.2 (irs1 complimented with XRCC2 [1]) upon exposure to 3-AB (A), ISQ (B) or NU1025 (C). The means (symbols) and standard deviation (bars) of at least three experiments are shown. Colony outgrowth assay was used;

20 Figure 2 is a graph showing cell survival in the presence of PARP inhibitor NU1025 in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complimented with functional BRCA2 gene (VC-8#13, VC-8+B2). Colony outgrowth assay was used;

25 Figure 3 is a histogram showing the percentage of the cells in apoptosis following a 72 hour incubation with NU1025;

30 Figure 4. (a) Western blot analysis of protein lysates isolated from MCF-7 ( $p53^{wt}$ ) or MDA-MB-231 ( $p53^{mut}$ ) breast cancer cells following 48 hours transfection with siRNA. (b) Colony outgrowth of siRNA-treated MCF-7 cells or (c) MDA-MB-231 cells following exposure to the PARP inhibitor NU1025. The means (symbols) and standard deviation (bars) of at least three experiments are shown.

Figure 5. BRCA2 deficient cells fail to repair a recombination lesion formed at replication forks by inhibitors of PARP. (a) Visualization of double strand breaks

(DSBs) in BRCA2 proficient or deficient cells following a 24-hour treatment with NU1025 (0.1 mM) by pulse-field gel electrophoresis. Hydroxyurea 2 mM was used as a positive control. (b) Visualisation of  $\gamma$ H2Ax foci in untreated V-C8+B2 and V-C8 cells. Number of cells containing  $\gamma$ H2Ax foci (c) or RAD51 foci (d) visualised in V-C8+B2 and V-C8 cells following a 24-hour treatment with NU1025 (10  $\mu$ M). The means (symbols) and standard errors (bars) of three to nine experiments are shown. (e) A suggested model for cell death induced in BRCA2 deficient cells.

Figure 6. PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion, causing death in absence of BRCA2. (a) RT-PCR on RNA isolated from SW480SN.3 cells treated with BRCA2, PARP-1 and PARP-2 siRNA in combinations as shown for 48 hours. (b) Clonogenic survival following 48-hours depletion of BRCA2, PARP-1 and PARP-2. The means (symbols) and standard deviation (bars) of at least three experiments are shown. Two and three stars designate statistical significance in *t-test*  $p<0.01$  and  $p<0.001$ , respectively. (c) Western blot for PARP-1 in SW480SN.3 cells treated with different siRNA.

Figure 7. (a) Visualisation of PAR polymers in untreated and (b) thymidine treated V79 cells (5 mM for 24 hours). (c) Percentage cells containing >10 sites of PARP activity following treatment with hydroxyurea (0.2 mM) and thymidine (5 mM). At least 300 nuclei were counted for each treatment and experiment. (d) Survival of V-C8+B2 cells following co-treatment with hydroxyurea or (e) thymidine and NU1025 (10  $\mu$ M). (f) The activity of PARP was measured by the level of free NAD(P)H<sup>11</sup>, following treatment with MMS, hydroxyurea (0.5 mM) or thymidine (10 mM). The means (symbol) and standard deviation (error bars) from at least three experiments are depicted.

Figure 8. (a) Visualisation of PAR polymers in untreated V-C8 and (b) V-C8+B2 cells. (c) Quantification of percentage cells containing >10 sites of PARP activity in untreated V-C8 and V-C8+B2 cells. (d) Level of NAD(P)H measured in untreated V-C8 and V-C8+B2 cells. Three stars designate  $p<0.001$  in *t-test*. (e) Visualization of RAD51 and sites of PARP activity in V79 cells following a 24-hour thymidine

treatment (5 mM). (f) A model for the role of PARP and HR at stalled replication forks.

Figure 9 is the human cDNA sequence of PARP-1;

5

Figure 10 is the human cDNA sequence of PARP-2;

Figure 11 is the human cDNA sequence of PARP-3;

10 Figure 12 is the human gDNA sequence of Tankyrase 1;

Figure 13 is the human mRNA sequence of Tankyrase 2;

Figure 14 is the human mRNA sequence of VPARP.

15

### Materials and Methods

#### Cytotoxicity of PARP inhibitors to HR-defective cells: XRCC2, XRCC3 or BRCA2

20 *Cell culture*

The irs1, irs1X2.1 and V79-4 cell lines were a donation from John Thacker [40] and the AA8, irs1SF and CXR3 cell lines were provided by Larry Thompson [41].

25 The VC-8, VC-8+B2, VC-8#13 were a gift from Malgorzata Zdzienicka [42]. All cell lines in this study were grown in Dulbecco's modified Eagle's Medium (DMEM) with 10% Foetal bovine serum and penicillin (100 U/ml) and streptomycin sulphate (100 µg/mL) at 37°C under an atmosphere containing 5% CO<sub>2</sub>.

#### *Toxicity assay - colony outgrowth assay*

30 500 cells suspended in medium were plated onto a Petri dish 4 hours prior to the addition of 3-AB, ISQ or NU1025. ISQ and NU1025 were dissolved in DMSO to a final concentration of 0.2% in treatment medium. 7 - 12 days later, when colonies could be observed, these colonies were fixed and stained with methylene blue in

methanol (4 g/l). Colonies consisting of more than 50 cells were subsequently counted.

#### Apoptosis experiments

5     $0.25 \times 10^6$  cells were plated onto Petri dishes and grown for 4 hours before treatment with NU1025. After 72 hours, cells were trypsinized and resuspended with medium containing any floating cells from that sample. The cells were pelleted by centrifugation and resuspended for apoptosis analysis with FITC-conjugated annexin-V and propidium iodine (PI) (ApoTarget, Biosource International) according to  
10 manufacturer's protocol. Samples were analysed by flow cytometry (Becton-Dickenson FACSort , 488 nm laser), and percentage of apoptotic cells was determined by the fraction of live cells (PI-negative) bound with FITC-conjugated annexin-V.

#### 15    Immunofluorescence

Cells were plated onto coverslips 4 h prior to 24-h treatments as indicated. Following treatments the medium was removed and coverslips rinsed once in PBS at 37°C and fixed as described elsewhere [2]. The primary antibodies and dilutions used in this study were; rabbit polyclonal anti PAR (Trevigen; 1:500), goat polyclonal anti Rad51  
20 (C-20, Santa Cruz; 1:200) and rabbit polyclonal anti Rad51 (H-92, Santa Cruz; 1:1000). The secondary antibodies were Cy-3-conjugated goat anti-rabbit IgG antibody (Zymed; 1:500), Alexa 555 goat anti-rabbit F(ab')<sub>2</sub> IgG antibody (Molecular Probes; 1:500), Alexa 546 donkey anti-goat IgG antibody (Molecular Probes; 1:500) and Alexa 488 donkey anti-rabbit IgG antibody (Molecular Probes; 1:500).  
25    Antibodies were diluted in PBS containing 3% bovine serum albumin. DNA was stained with 1 µg/ml To Pro (Molecular Probes). Images were obtained with a Zeiss LSM 510 inverted confocal microscope using planapochromat 63X/NA 1.4 oil immersion objective and excitation wavelengths 488, 546 and 630 nm. Through focus maximum projection images were acquired from optical sections 0.50 µm apart  
30 and with a section thickness of 1.0 µm. Images were processed using Adobe PhotoShop (Abacus Inc). At least 300 nuclei were counted on each slide and those containing more than 10 RAD51 foci or sites of PARP activity were classified as positive.

PARP activity assays

A water-soluble tetrazolium salt (5mM WST-8) was used to monitor the amount of NAD(P)H through its reduction to a yellow coloured formazan dye[43]. 5000 cells were plated in at least triplicate into wells of a 96 well plate and cultured in 100 $\mu$ l normal growth media for 4 h at 37°C. CK8 buffer (Dojindo Molecular Technology, Gaithersburg, USA), containing WST-8, was then added either with or without treatment with DNA damaging agents at concentrations indicated. Reduction of WST-8 in the presence of NAD(P)H was determined by measuring visible absorbance (OD<sub>450</sub>) every 30 min. A medium blank was also prepared containing just media and CK8 buffer. Changes in NAD(P)H levels were calculated by comparing the absorbance of wells containing cells treated with DNA damaging agents and those treated with DMSO alone. Alternately relative levels of NAD(P)H in different cells lines were calculated after 4 h incubation in CK8 buffer.

The ability of NU1025 to inhibit PARP-1 activity was also assayed in permeabilised cells using a modification of the method of Halldorsson *et al* [44], and described in detail elsewhere [45]. Briefly: 300  $\mu$ l of NU1025-treated (15 min) permeabilised cells were incubated at 26°C with oligonucleotide (final conc. 2.5  $\mu$ g/ml), 75  $\mu$ M NAD + [<sup>32</sup> P] NAD (Amersham Pharmacia, Amersham, UK) in a total volume of 400  $\mu$ l. The reaction was terminated after 5 min by adding ice cold 10%TCA 10%Na Ppi for 60 min prior to filtering through a Whatman GF/C filter (LabSales, Maidstone, UK), rinsed 6x with 1% TCA 1% NaPpi, left to dry and incorporated radioactivity was measured to determine PARP-1 activity. Data are expressed as pmol NAD incorporated/10<sup>6</sup> cells by reference to [<sup>32</sup> P] NAD standards.

25 Pulse-field gel electrophoresis

1.5x10<sup>6</sup> cells were plated onto 100 mm dishes and allowed 4 h for attachment. Exposure to drug was for 18 h after which cells were trypsinised and 10<sup>6</sup> cells melted into each 1% agarose insert. These inserts were incubated as described elsewhere (8) and separated by pulse-field gel electrophoresis for 24 h (BioRad; 120° angle, 60 to 240 s switch time, 4 V/cm). The gel was subsequently stained with ethidium bromide for analysis.

siRNA treatment

Predesigned BRCA2 SMARTpool and scrambled siRNAs were purchased (Dharmacon, Lafayette, CO). 10000 cells seeded onto 6 well plates and left over night before transfected with 100nM siRNA using Oligofectamine Reagent (Invitrogen) according to manufacturers instructions. Cells were then cultured in normal growth media for 48 h prior to trypsinisation and replating for toxicity assays. Suppression of BRCA2 was confirmed by Western blotting (as described previously [46]) of protein extracts treated with siRNA with an antibody against BRCA2 (Oncogene, Nottingham, UK).

10

EXAMPLESHomologous recombination deficient cells are hypersensitive to PARP-1 inhibition

To investigate the involvement of HR in cellular responses to inhibition of PARP-1, the effects of PARP-1 inhibitors on the survival of HR repair deficient cell lines were studied. It was found that cells deficient in HR (i.e., *irs1SF* which is defective in *XRCC3* or *irs1* which is defective in *XRCC2* [see Table 1] were very sensitive to the toxic effect of 3-aminobenzamide (3-AB) and to two more potent inhibitors of PARP-1: 1,5-dihydroxyisoquinoline (ISQ; [37]) or 8-hydroxy-2-methylquinazolinone (NU1025 [38, 39]) (Figure 1). The sensitivity in *irs1SF* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC3* gene (CXR3). Similarly, the sensitivity in *irs1* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC2* gene (*irs1X2.2*).

25

BRCA2 deficient cells are hypersensitive to PARP-1 inhibition

The survival of BRCA2 deficient cells (VC8) and wild type cells (V79Z) in the presence of inhibitors of PARP-1 was investigated. It was found that VC8 cells are very sensitive to the toxic effect of NU1025 (Figure 2). The sensitivity in VC8 cells was corrected by the introduction of a functional BRCA2 gene either on chromosome 30 13 (VC8#13) or on an overexpression vector (VC8+B2). This result demonstrates that the sensitivity to PARP-1 inhibitors is a direct consequence of loss of the BRCA2 function.

To investigate if inhibition of PARP-1 triggers apoptosis in BRCA2 deficient cells, the level of apoptosis 72 hours following exposure to NU1025 was investigated. It was found that NU1025 triggered apoptosis only in VC8 cells, showing that loss of PARP-1 activity in BRCA2 deficient cells triggers this means of death (Figure 3).

5

BRCA2 deficient breast cancer cells are hypersensitive to PARP-1 inhibition

It was examined whether the MCF7 (wild-type p53) and MDA-MB-231 (mutated p53) breast cancer cell lines displayed a similar sensitivity to NU1025 upon depletion of BRCA2. It was found that PARP inhibitors profoundly reduced the survival of MCF7 and MDA-MB-231 cells only when BRCA2 was depleted with a mixture of BRCA2 siRNA (Figure 4). This shows that BRCA2 depleted breast cancer cells are sensitive to PARP inhibitors regardless of p53 status.

BRCA2 deficient cells die from PARP-1 inhibition in absence of DNA double-strand  
15 breaks (DSBs) but in presence of  $\gamma$ H2Ax

HR is known to be involved in the repair of DSBs and other lesions that occur during DNA replication [2]. To determine whether the sensitivity of BRCA2 deficient cells is the result of an inability to repair DSBs following NU1025 treatment, the accumulation of DSBs in V79 and V-C8 cells was measured following treatments

20 with highly toxic levels of NU1025. It was found that no DSBs were detectable by pulsed field gel electrophoretic analysis of DNA obtained from the treated cells (Figure 5A), suggesting that low levels of DSBs or other recombinogenic substrates accumulated following PARP inhibition in HR deficient cells, which trigger  $\gamma$ H2Ax

Figure 5B). The reason why BRCA2 deficient cells die following induction of these 25 recombinogenic lesions is likely to be due to an inability to repair such lesions. To test this, the ability of BRCA2 deficient V-C8 cells and BRCA2 complimented cells to

form RAD51 foci in response to NU1025 was determined. It was found that RAD51 foci were indeed induced in V-C8+B2 cells following treatment with NU1025 (statistically significant in *t-test*  $p<0.05$ ; Figure 5D). This indicates that the

30 recombinogenic lesions trigger HR repair in these cells allowing them to survive. In contrast, the BRCA2 deficient V-C8 cells were unable to form RAD51 foci in response to NU1025 treatment (Figure 5D) indicating no HR, which would leave the recombinogenic lesions unrepaired and thus cause cell death.

PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion

There are two major PARPs present in the nucleus in mammalian cells, PARP-1 and

5 PARP-2 and all reported PARP inhibitors inhibit both. In order to distinguish which  
PARP was responsible for the effect, we tested if the absence of PARP-1 and/or  
PARP-2 results in accumulation of toxic lesions, by depleting these and BRCA2 with  
siRNA in human cells (Figure 6a). We found that the clonogenic survival was  
significantly reduced when both PARP-1 and BRCA2 proteins were co-depleted from  
10 human cells (Figure 6b). Depletion of PARP-2 with BRCA2 had no effect on the  
clonogenic survival and depletion of PARP-2 in PARP-1 and BRCA2 depleted cells  
did not result in additional toxicity. These results suggest that PARP-1 and not PARP-  
15 2 is responsible for reducing toxic recombinogenic lesions in human cells. The  
cloning efficiency was only reduced to 60% of control in PARP-1 and BRCA2 co-  
depleted cells, while no HR deficient cells survived treatments with PARP inhibitors.  
This is likely to do with incomplete depletion of the abundant PARP-1 protein by  
siRNA (Figure 6c), which might be sufficient to maintain PARP-1 function in some  
of the cells.

20 PARP-1 is activated by replication inhibitors

HR is also involved in repair of lesions occurring at stalled replication forks, which  
may not involve detectable DSBs [2]. To test if PARP has a role at replication forks,  
PARP activation in cells treated with agents (thymidine or hydroxyurea) that

25 retard or arrest the progression of DNA replication forks was examined. Thymidine  
depletes cells of dCTP and slows replication forks without causing DSBs.  
Hydroxyurea depletes several dNTP and block the replication fork, which is  
associated with the formation of DSBs at replication forks [2]. Both of these agents  
potently induce HR [2]. V79 hamster cells treated for 24 hours with thymidine or  
30 hydroxyurea were stained for PAR polymers. This revealed a substantial increase in  
the number of cells containing sites of PARP activity (Figure 7C). This result suggests  
a function for PARP at stalled replication forks. It was also shown that inhibition of  
PARP with NU1025 enhances the sensitivity to thymidine or hydroxyurea in V-  
C8+B2 cells (Figure 7D,E). This result suggests that PARP activity is important in

repair of stalled replication forks or alternatively that it prevents the induction of death in cells with stalled replication forks.

PARP is rapidly activated at DNA single-strand breaks (SSB) and attracts DNA repair  
5 enzymes [3-6]. Methylmethane sulphonate (MMS) causes alkylation of DNA, which is repaired by base excision repair. PARP is rapidly activated by the SSB-intermediate formed during this repair, which depletes the NAD(P)H levels (Figure 7F). We found that the activation of PARP and reduction of NAD(P)H levels is much slower following thymidine or hydroxyurea treatments. This slow PARP activation can be  
10 explained by the indirect action of thymidine and hydroxyurea and the time required to accumulate stalled replication forks as cells enter the S phase of the cell cycle.

#### PARP-1 and HR have separate roles at stalled replication forks

15 The number sites of PARP activity in untreated BRCA2 deficient V-C8 cells was determined. It was found that more V-C8 cells contain sites of PARP activity compared to V-C8+B2 cells (Figure 8A,B,C). Also, the V-C8 cells have lower free NAD(P)H levels than the corrected cells (Figure 8D), as a likely result of the increased PARP activity. Importantly these sites of PARP activity do not overlap with  
20 RAD51 foci (Figure 8E).

The results herein suggest that PARP and HR have separate roles in the protection or rescue of stalled replication forks (Figure 8F). A loss of PARP activity can be compensated by increased HR while a loss of HR can be compensated by increased  
25 PARP activity. However, loss of both these pathways leads to accumulation of stalled replication forks and to death, as in the case of PARP inhibited BRCA2 deficient cells.

As shown in the model outlined in Figure 8F PARP and HR have complementary  
30 roles at stalled replication forks. (i) Replication forks may stall when encountering a roadblock on the DNA template. In addition, they may also stall temporarily, due to lack of dNTPs or other replication co-factors. (ii) PARP binds stalled replication forks or other replication-associated damage, triggering PAR polymerization. Resulting negatively charged PAR polymers may protect stalled replication forks, by repelling

proteins that normally would process replication forks (e.g., resolvases), until the replication fork can be restored spontaneously when dNTPs or other co-factors become available. Alternatively, PAR polymers or PARP may attract proteins to resolve the replication block by other means. (iii) In absence of PARP activity, HR 5 may be used as an alternative pathway to repair stalled replication forks. This compensatory model explains the increased level of HR and RAD51 foci found in PARP deficient cells<sup>3-5</sup> and higher PARP activity found in HR deficient cells (i.e. V-C8). Spontaneous replication blocks/lesions are only lethal in the absence of both PARP and HR.

10

**Table 1.** Genotype and origin of cell lines used in this study.

| Cell line | Genotype                  | Defect                                      | Origin | Reference |
|-----------|---------------------------|---|--------|-----------|
| AA8       | Wt                        | Wt  | CHO    | [41]      |
| irs1SF    | <i>XRCC3</i> <sup>-</sup> | <i>XRCC3</i> <sup>-</sup> , deficient in HR | AA8    | [41]      |
| CXR3      | <i>XRCC3</i> <sup>-</sup> | Wt<br>+ <i>hXRCC3</i>                       | irs1SF | [41]      |
| V79-4     | Wt                        | Wt  | V79    | [40]      |
| irs1      | <i>XRCC2</i> <sup>-</sup> | <i>XRCC2</i> <sup>-</sup> , deficient in HR | V79-4  | [40]      |
| irs1X2.2  | <i>XRCC2</i> <sup>-</sup> | Wt<br>+ <i>hXRCC2</i>                       | irs1   | [40]      |
| V79-Z     | <i>Wt</i>                 | Wt  | V79    | [42]      |
| VC8       | <i>BRCA2</i> <sup>-</sup> | <i>BRCA2</i> <sup>-</sup> , deficient in HR | V79-Z  | [42]      |
| VC8#13    | <i>BRCA2</i> <sup>-</sup> | Wt<br>+ <i>hBRCA2</i>                       | VC8    | [42]      |
| VC8+B2    | <i>BRCA2</i> <sup>-</sup> | Wt<br>+ <i>hBRCA2</i>                       | VC8    | [42]      |

## REFERENCES:

- [1] A.R. Venkitaraman Cancer susceptibility and the functions of BRCA1 and BRCA2, *Cell* 108 (2002) 171-182.
- 5 [2] C. Lundin, K. Erixon, C. Arnaudeau, N. Schultz, D. Jenssen, M. Meuth and T. Helleday Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells, *Mol Cell Biol* 22 (2002) 5869-5878.
- 10 [3] D. D'Amours, S. Desnoyers, I. D'Silva and G.G. Poirier Poly(ADP-ribosylation reactions in the regulation of nuclear functions, *Biochem J* 342 (1999) 249-268.
- [4] Z. Herceg and Z.Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death, *Mutat Res* 477 (2001) 97-110.
- 15 [5] T. Lindahl, M.S. Satoh, G.G. Poirier and A. Klungland Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks, *Trends Biochem Sci* 20 (1995) 405-411.
- [6] M.S. Satoh and T. Lindahl Role of poly(ADP-ribose) formation in DNA repair, *Nature* 356 (1992) 356-358.
- 20 [7] S. Shall and G. de Murcia Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?, *Mutat Res* 460 (2000) 1-15.
- [8] Z.Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, K. Schulze-Osthoff and E.F. Wagner PARP is important for genomic stability but dispensable in apoptosis, *Genes Dev* 11 (1997) 2347-2358.
- 25 [9] C.M. Simbulan-Rosenthal, B.R. Haddad, D.S. Rosenthal, Z. Weaver, A. Coleman, R. Luo, H.M. Young, Z.Q. Wang, T. Ried and M.E. Smulson Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA, *Proc Natl Acad Sci U S A* 96 (1999) 13191-13196.
- 30 [10] J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F.J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walztinger, P. Chambon and G. de Murcia Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells, *Proc Natl Acad Sci U S A* 94 (1997) 7303-7307.

- [11] F. d'Adda di Fagagna, M.P. Hande, W.M. Tong, P.M. Lansdorp, Z.Q. Wang and S.P. Jackson Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability, *Nat Genet* 23 (1999) 76-80.
- [12] E. Samper, F.A. Goytisolo, J. Menissier-de Murcia, E. Gonzalez-Suarez, J.C. Cigudosa, G. de Murcia and M.A. Blasco Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability, *J Cell Biol* 154 (2001) 49-60.
- [13] C. Morrison, G.C. Smith, L. Stingl, S.P. Jackson, E.F. Wagner and Z.Q. Wang Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis, *Nat Genet* 17 (1997) 479-482.
- [14] V. Schreiber, D. Hunting, C. Trucco, B. Gowans, D. Grunwald, G. De Murcia and J.M. De Murcia A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage, *Proc Natl Acad Sci U S A* 92 (1995) 4753-4757.
- [15] J.H. Kupper, M. Muller and A. Burkle Trans-dominant inhibition of poly(ADP-ribosylation) potentiates carcinogen induced gene amplification in SV40-transformed Chinese hamster cells, *Cancer Res* 56 (1996) 2715-2717.
- [16] J. Magnusson and C. Ramel Inhibitor of poly(ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells in vivo in *Drosophila melanogaster*, *Mutagenesis* 5 (1990) 511-514.
- [17] A.S. Waldman and B.C. Waldman Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation), *Nucleic Acids Res* 19 (1991) 5943-5947.
- [18] A. Semionov, D. Cournoyer and T.Y. Chow Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts, *Nucleic Acids Res* 27 (1999) 4526-4531.
- [19] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia and G. de Murcia Involvement of poly(ADP-ribose) polymerase in base excision repair, *Biochimie* 81 (1999) 69-75.

- [20] F. Dantzer, G. de La Rubia, J. Menissier-De Murcia, Z. Hostomsky, G. de Murcia and V. Schreiber Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1, *Biochemistry* 39 (2000) 7559-7569.
- 5 [21] L. Tentori, I. Portarena and G. Graziani Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors, *Pharmacol Res* 45 (2002) 73-85.
- [22] T. Lindahl and R.D. Wood Quality control by DNA repair, *Science* 286 (1999) 1897-1905.
- 10 [23] K.W. Caldecott DNA single-strand break repair and spinocerebellar ataxia, *Cell* 112 (2003) 7-10.
- [24] D. D'Amours and S.P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling, *Nat Rev Mol Cell Biol* 3 (2002) 317-327.
- [25] A.D. D'Andrea and M. Grompe The Fanconi anaemia/BRCA pathway, *Nat Rev Cancer* 3 (2003) 23-34.
- 15 [26] S.P. Jackson Sensing and repairing DNA double-strand breaks, *Carcinogenesis* 23 (2002) 687-696.
- [27] R. Kanaar, J.H. Hoeijmakers and D.C. van Gent Molecular mechanisms of DNA double strand break repair, *Trends Cell Biol* 8 (1998) 483-489.
- 20 [28] D.C. van Gent, J.H. Hoeijmakers and R. Kanaar Chromosomal stability and the DNA double-stranded break connection, *Nat Rev Genet* 2 (2001) 196-206.
- [29] S.L. Neuhausen and E.A. Ostrander Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2, *Genet Test* 1 (1997) 75-83.
- 25 [30] G. Kuperstein, W.D. Foulkes, P. Ghadirian, J. Hakimi and S.A. Narod A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes, *Clin Genet* 57 (2000) 213-220.
- [31] A. Chiarugi Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited, *Trends Pharmacol Sci* 23 (2002) 122-129.
- 30 [32] C.R. Calabrese, M.A. Batey, H.D. Thomas, B.W. Durkacz, L.Z. Wang, S. Kyle, D. Skalitzky, J. Li, C. Zhang, T. Boritzki, K. Maegley, A.H. Calvert, Z. Hostomsky, D.R. Newell and N.J. Curtin Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies, *Clin Cancer Res* 9 (2003) 2711-2718.
- [33] D. Ferraris, Y.S. Ko, T. Pahutski, R.P. Ficco, L. Serdyuk, C. Alemu, C. Bradford, T. Chiou, R. Hoover, S. Huang, S. Lautar, S. Liang, Q. Lin, M.X.

- Lu, M. Mooney, L. Morgan, Y. Qian, S. Tran, L.R. Williams, Q.Y. Wu, J. Zhang, Y. Zou and V. Kalish Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries, *J Med Chem* 46 (2003) 3138-3151.
- [34] K.J. Dillon, G.C. Smith and N.M. Martin A FlashPlate assay for the identification of PARP-1 inhibitors, *J Biomol Screen* 8 (2003) 347-352.
- [35] A.J. Pierce, R.D. Johnson, L.H. Thompson and M. Jasin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, *Genes Dev* 13 (1999) 2633-2638.
- [36] R.D. Johnson, N. Liu and M. Jasin Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination, *Nature* 401 (1999) 397-399.
- [37] G.M. Shah, D. Poirier, S. Desnoyers, S. Saint-Martin, J.C. Hoflack, P. Rong, M. ApSimon, J.B. Kirkland and G.G. Poirier Complete inhibition of poly(ADP-ribose) polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress, *Biochim Biophys Acta* 1312 (1996) 1-7.
- [38] R.J. Griffin, S. Srinivasan, K. Bowman, A.H. Calvert, N.J. Curtin, D.R. Newell, L.C. Pemberton and B.T. Golding Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), *J Med Chem* 41 (1998) 5247-5256.
- [39] S. Boulton, L.C. Pemberton, J.K. Porteous, N.J. Curtin, R.J. Griffin, B.T. Golding and B.W. Durkacz Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors, *Br J Cancer* 72 (1995) 849-856.
- [40] C.S. Griffin, P.J. Simpson, C.R. Wilson and J. Thacker Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation, *Nat Cell Biol* 2 (2000) 757-761.
- [41] R.S. Tebbs, Y. Zhao, J.D. Tucker, J.B. Scheerer, M.J. Siciliano, M. Hwang, N. Liu, R.J. Legerski and L.H. Thompson Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene, *Proc Natl Acad Sci U S A* 92 (1995) 6354-6358.

- [42] M. Kraakman-van der Zwet, W.J. Overkamp, R.E. van Lange, J. Essers, A. van Duijn-Goedhart, I. Wiggers, S. Swaminathan, P.P. van Buul, A. Errami, R.T. Tan, N.G. Jaspers, S.K. Sharan, R. Kanaar and M.Z. Zdzienicka Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions, Mol Cell Biol 22 (2002) 669-679.
- [43] J. Nakamura, S. Asakura, S.D. Hester, G. de Murcia, K.W. Caldecott and J.A. Swenberg Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time, Nucleic Acids Res 31 (2003) e104.
- [44] H. Halldorsson, D.A. Gray and S. Shall Poly (ADP-ribose) polymerase activity in nucleotide permeable cells, FEBS Lett 85 (1978) 349-352.
- [45] K. Grube, J.H. Kupper and A. Burkle Direct stimulation of poly(ADP ribose) polymerase in permeabilized cells by double-stranded DNA oligomers, Anal Biochem 193 (1991) 236-239.
- [46] C. Lundin, N. Schultz, C. Arnaudeau, A. Mohindra, L.T. Hansen and T. Helleday RAD51 is Involved in Repair of Damage Associated with DNA Replication in Mammalian Cells, J Mol Biol 328 (2003) 521-535.
- [47] Schreider et al., Journal of Biological Chemistry 277: 23028-23036 (2002).

CLAIMS

1. Use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.  
5
2. The use as claimed in claim 1 wherein the enzyme is poly(ADP-ribose) polymerase (PARP).
- 10 3. The use as claimed in claim 2 wherein the agent is a PARP inhibitor.
4. The use as claimed in claim 3 wherein the PARP inhibitor is selected from the group consisting of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 and tankyrase 2.  
15
5. The use as claimed in claim 4 wherein the PARP is PARP-1.
6. The use as claimed in claim 1 or claim 2 wherein the agent is an RNAi molecule specific to a PARP gene.  
20
7. The use as claimed in claim 6 wherein the RNAi molecule is derived from a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:
  - a) a nucleic acid sequence as represented by the sequence in Figure 9, 10, 25 11, 12, 13 or 14, or a fragment thereof;
  - b) a nucleic acid sequence which hybridises to the nucleic acid sequences of Figure 9, 10, 11, 12, 13 or 14, and encodes a gene for PARP; or
  - c) a nucleic acid sequence which comprises sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a) and (b).  
30
8. The use as claimed in claim 6 or 7 wherein the RNAi molecule comprises the nucleic acid sequence aaa agc cau ggu gga gua uga.

9. The use as claimed in claim 6 or 7 wherein the RNAi molecule consists of the nucleic acid sequence aag acc aau cuc ucc agu uca ac.

10. The use as claimed in claim 6 or 7 wherein the RNAi molecule consists of the  
5 nucleic acid sequence aag acc aac auc gag aac aac.

11. The use as claimed in any preceding claim wherein the defect is a mutation in a gene encoding a protein involved in HR.

10 12. The use as claimed in any of claims 1 to 10 wherein the defect is the absence of a gene encoding a protein involved in HR.

13. The use as claimed in any of claims 1 to 10 wherein the defect is in the expression of a gene encoding a protein involved in HR.

15 14. The use as claimed in any preceding claim wherein the gene that mediates HR is selected from the group consisting of XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52,  
20 RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Eme1, DDS1 and BARD.

15. The use as claimed in any preceding claim in the treatment of cancer.

25 16. The use as claimed in claim 15 wherein the cancer is selected from the group consisting of lung, colon, pancreatic, gastric, ovarian, cervical, breast and prostate cancer.

30 17. The use as claimed in claim 15 or 16 wherein the cancer is in a human.

18. The use as claimed in any of claims 15 to 17 wherein the cancer is gene-linked hereditary cancer.

19. The use as claimed in claim 18 wherein the cancer is breast cancer.
20. The use as claimed in any of claims 15 to 19 wherein the cancer cells to be treated are defective in BRCA1 expression.  
5
21. The use as claimed in any of claims 15 to 19 wherein the cancer cells to be treated are defective in BRCA2 expression.
22. The use as claimed in claim 20 or 21 wherein the cancer cells are partially deficient in BRCA1 and/or BRCA2 expression.  
10
23. The use as claimed in claim 20 or 21 wherein the cancer cells are totally deficient in BRCA1 and/or BRCA2 expression.
- 15 24. The use as claimed in any preceding claim wherein the gene that mediates HR is a tumour suppressor gene.
25. The use as claimed in claim 24 wherein the tumour suppressor gene is BRCA1.
- 20 26. The use as claimed in claim 24 wherein the tumour suppressor gene is BRCA2
27. Use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.
- 25 28. The use as claimed in claim 27 wherein the HR defective cells are cancer cells.
29. The use as claimed in claim 28 wherein the cancer cells defective in HR are partially deficient in HR.
- 30 30. The use as claimed in claim 28 wherein the cancer cells defective in HR are totally deficient in HR.
31. A method of treatment of a disease or condition in a mammal, including human, which is caused by a genetic defect in a gene that mediates homologous

recombination, which method comprises administering to the mammal a therapeutically effective amount of an agent that inhibits the activity of an enzyme that mediates repair of DNA strand breaks.

- 5 32. A method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor.


5 **Figure 1.**

Figure 2.




Figure 3




Figure 4

4/20








Figure 5A

5/20



6/20








FIG. 6





FIG. 7



## FIGURE 9

11/20

2821 ggtgggtgag aagcagaaaag taaatattat ccagttcgac acaggttaca aggagctatt  
2881 ttctgtatcc aagcatatca caagcaatac cgcggcagca gagttcatca tgtctgccac  
2941 acctaccatg gggAACACAG acttctggaa aacactccga tatcttagct tattgtaccc  
3001 tgctcgaggg tcacggaca tcctccttgt gtctgatggg cacccagg atgagagcct  
3061 gacattacag ctctgtggaa ggagccgccc gcacaccagg ttattgcct gggatcgg  
3121 ttctacagca aatcgtaacg tcttaaggat ttgtccccag tttggggccg gagtatttga  
3181 atatttaat gcaaaaatcca agcatagttt gagaAAAACAG atagaagacc aaatgaccag  
3241 gctatgttct ccgagttgcc actctgtctc cgtcaaattgg cagcaactca atccagatgc  
3301 gcccggggcc ctgcaggccc cagcccaagg gccatcctt ttcgcaatg atcgactcct  
3361 tgtctatggta ttcatccctc actgcacaca ggcaactctg tgtgcactaa ttcaagagaa  
3421 agaattttgt acaatgggtt cgactactga gcttcagaag acaactggaa ctatgtatcca  
3481 caagctggca gcccggctc taatcagaga ttatcagatgg ggcattctc acgaaaaatga  
3541 aaccagtcat gagatggaaa aacaaacattt gaaatcttg attattaaac tcagtaaaga  
3601 aaactctctc ataacacaat ttacaagctt tgtggcaggat gagaAAAGGG atgagaatga  
3661 gtcacctttt cctgatattc caaaagttt tgaacttatt gccaagaag atgttagactt  
3721 cctgcctac atgagctggc agggggaaacc ccaagaagcc gtcaggaacc agtctttt  
3781 agcatctctt gaggggccat aattacgtttt atccaaacga aaacatagga aaattccatt  
3841 ttccaaaaga aaaatggaaat tatctcagcc agaaggtttctt gaagatttg aagaggatgc  
3901 cttaggtgtt ctaccagctt tcacatcaaa ttggaaacgt ggacgtgtgg aaaagctatt  
3961 ggatttaagt tggacagatg catgtaaacc aacagcaact gaaccactat ttaagaaagt  
4021 cagtccatgg gaaacatcta cttagctt ttggcttattt ttggctccgg ccgtgggttc  
4081 ctatcttacc ccgactaccc ggcgtcacag tcctgcctt ttgtctttt ctcataatcg  
4141 tcaggttagct agttcggtt cagctgcctc tcccagacag ttgtatgc tcaatttc  
4201 ccaaggccctt gtgcctggca ctgtgctga ctggatccca cagtcggcgt ctgtccac  
4261 aggacccc cagaacccac ctctgcacc ctatgtggc attttttt cagggagctc  
4321 attaagctt gcacagtctg ctccactgca acatcttggaa ggcttacta ccaggccctc  
4381 tgctggcacc ttccctgagc tggattctcc ccagctcat ttctcttcc ctacagaccc  
4441 tgatccatc agaggtttgg ggtcttatca tccctctgct tactcttcc ttcattttca  
4501 acctccgca gccttttga ctgccaacctt taggctgcca atggctctg cttagtgc  
4561 ggcttttgc agtcagtccc ggactacccc agtagatctc tttttttttt aagaatcgt  
4621 aggacgtctc gaaggaagtc gatgtctgtt ctgttttcaaaggatctg acacagaaag  
4681 tgatgagctt tcagaagatc ttcaagacag ctgtttttt caaataaaat gtgatcaca  
4741 agatgacatg atcccggtt ttctggaaatgaaaaggatg gatgaaatag tttttttttt  
4801 acactggcag gatgtgtgc ctggacaga actctctgtt ctacagacag aggtatggctt  
4861 ctggaaactt acaccagaac tggacttattt attaaatctt aatacaatg gtttgcacag  
4921 ctttttttttt caaaaaggca ttcaatctt aggtgtttttt ggaagagaat gtctcttgg  
4981 cctaattgcc acaatgtgg tactacagtt tattgcacc aggtgtggaa aagaggaaat  
5041 agtggatcaaa tcactgtatca aatggatca cccttcttattt tccaggaata ttccctgg  
5101 ttggggca ataaagcaag caagtgtatgg ggttggaaactt actgttggac agtacccatc  
5161 tatctggcca cggcttggaa tggggaaacgtt ctggactctt gccaaggccatc agttgtgg  
5221 actccagccca ataaggactt tttttttttt tttttttttt tttttttttt  
5281 agtcaaatgtt aactgtatgg tttttttttt tttttttttt tttttttttt  
5341 ataaatgtt tttttttttt tttttttttt tttttttttt tttttttttt  
5401 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt  
5461 cttaaaaat

Figure 10

1 ctagaattca gggccgctg aattctaggc ggccggcg cgacggagca cggccggcgg  
61 cagggcgaga gcattaaatg aaagcaaaaag agttaataat ggcaacacgg ctccagaaga  
121 ctctccccct gccaagaaaa ctcgttagatg ccagagacag gagtcggaaa agatgcctgt  
181 ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgccaggaag  
241 gtcatgggcc agcaaaggg tctctgaatc tgtgaaggcc ttgctgttaa agggcaaagc  
301 tcctgtggac ccagagtgtc cagccaagggt gggaaaggct catgtgtatt gtgaaggaaa  
361 tcatgtctat gatgtcatgc taaatcagac caatctccag ttcaacaaca acaagtacta  
421 tctgattcag ctattagaag atgatgccc gaggaacttc agtgtttgga tgagatgggg  
481 ccgagttggg aaaatgggac agcacagcct ggtggcttgt tcaggcaatc tcaacaaggc  
541 caaggaaatc ttccagaaga aattccttga caaaaacgaaa aacaattggg aagatcgaga  
601 aaagtttgag aaggcctg gaaaatatga tatgctacag atggactatg ccaccaatac  
661 tcaggatgaa gaggaaacaa aaaaagagga atctcttaaa tctcccttga agccagagtc  
721 acagcttagat ctccgggtac aggagttat aaagttgatc tgaatgttc aggccatgga  
781 agaaatgtatg atgaaaatga agtataatac caagaaagcc ccacttggg agctgacagt  
841 ggcacaaatc aaggcagggtt accagtctt taagaagatt gaggattgtt ttccggctgg  
901 ccagcatgga cgagctctca tggaaagcatg caatgaattc tacaccagga ttccgcatga  
961 ctttggactc cgtactcctc cactaatccg gacacagaag gaactgtcag aaaaaataca  
1021 attactagag gctttggag acattgaaat tgctattaag ctggtaaaaa cagagctaca  
1081 aagcccagaa caccattgg accaacacta tagaaaccta catttgccct tgcgccccct  
1141 tgaccatgaa agttacgagt tcaaagtgtat ttcccagtac ctacaatcta cccatgtcc  
1201 cacacacagc gactatacca tgaccctgct ggatttgitt gaagtggaga aggatggtga  
1261 gaaagaagcc ttcaagaggg accttcataa caggatgtt ctatggcatg ttccaggat  
1321 gagtaactgg gtggaatct tgagccatgg gcttcgaatt gccccacctg aagctcccat  
1381 cacagggtac atgtttggga aaggaatcta ctttgctgac atgtttcca agagtccaa  
1441 ttactgttt gcctctcgcc taaagaatac aggactgctg ctcttatcag aggtagctt  
1501 aggtcagtgt aatgaactac tagaggccaa tcctaaggcc gaaggattgc ttcaaggtaa  
1561 acatagcacc aaggggctgg gcaagatggc tcccagtct gcccaactcg tcaccctgaa  
1621 tgggagttaca gtgcatttag gaccagcaag tgacacagga attctgaatc cagatggta  
1681 taccctcaac tacaatgaat atattgtata taaccccaac caggtccgtt tgccgtacct  
1741 tttaaagggtt cagtttaatt tccttcagct gtggtaatg ttgatcttaa ataaaccaga  
1801 gatctgatct tcaagaaga aaataaggcag tggtaatctt gtgaattttg tgatattta  
1861 tggtaataaaaa actgtacagg tctaaaaaaaaaaaaaaaaaaaaaaaaaaaa

//

Figure 11

1 tgggacttgtt cgccctgactc ggcctgcccc agcctctgt tcaccccact ggtggccaaa  
61 tagccatgt ctaatcccc acacaagctc atccccggcc tctgggattt tggttggattt  
121 ttccttaat tcacccctga ggctcatgga gagttgctag acctggact gcccctggag  
181 ggcacaccaa ccaggccggg tggcagccag gaccctccc atgcccctgc ttttcttggc  
241 catggctcca aagccgaagc cctgggtaca gactgaggac cctgagaaga agaaggcccg  
301 gcaggcagga agggaggagg accccttcg ctccaccgct gaggccctca aggccatacc  
361 cgcagagaag cgccataatcc gcgtggatcc aacatgtcca ctcagcagca acccccggac  
421 ccaggtgtat gaggactaca actgcaccctt gaaccagacc aacatcgaga acaacaacaa  
481 caagtctac atcattccagc tgctccaaga cagcaaccgc ttctcacct gctggAACCG  
541 ctggggccgt gtggagagg tcggccatgc aaagatcaac cacttcacaa ggctagaaga  
601 tgcaaagaag gacttgaga agaaatttcg ggaaaagacc aagaacaact gggcagagcg  
661 ggaccactt gtgtctcacc cggcaagta cacacttatac gaagtacagg cagaggatga  
721 ggcaggaa gctgttgtga aggtggacag aggccagtg aggactgtga ctaagcgggt  
781 gcagccctgc tccctggacc cagccacgca gaagctcatc actaacatct tcagcaagga  
841 gatgtcaag aacaccatgg ccctcatgga cctggatgt aagaagatgc ccctggaaaa  
901 gctgagcaag caacagattt cacggggttt cgaggccctg gaggcgctgg aggaggccct  
961 gaaaggcccc acggatggtg gccaaagctt ggaggagctg tccctcacact ttacaccgt  
1021 catcccac aactcggcc acagccagcc cccgcccatac aattccctg agcttctgca  
1081 ggccaagaag gacatgtgc tggcgtggc ggacatcgag ctggcccagg ccctgcaggc  
1141 agtctctgag caggagaaga cggtgagga ggtgccacac cccctggacc gagactacca  
1201 gcttctcaag tgccagctgc agctgctaga ctctggagca cctgagtaca aggtgataca  
1261 gacctactta gaacagactg gcagcaacca caggtgcctt acactcaac acatctggaa  
1321 agtaaaccaa gaagggggagg aagacagattt ccaggcccac tccaaactgg gtaatcgaa  
1381 gctgctgtgg catggcacca acatggccgtt ggtggccggc atccctacta gtggcgtccg  
1441 catcatgcca cattctgggtt ggcgtgtgg caagggcatc tacttgctt cagagaacag  
1501 caagtctactt ggatgttta ttggcatgaa gtgtggggcc caccatgtcg gctacatgtt  
1561 cctgggttagt gtggccctgg gcagagagca ccatatcaac acggacaacc ccagctgaa  
1621 gagccacactt cctggcttcg acagtgtcat tgcccggggc cacaccggc ctgatccgac  
1681 ccaggacact gagttggagc tggatggca gcaagtggtg gtggcccagg gccagccgt  
1741 gcccctggccca gagttcagca gtcacattt ctccacatc gagttacacta tctaccagga  
1801 gagccagtgt cgcctgcgtt acctgctggt ggtccacactc tgagtggccgg ccctgtcccc  
1861 cggggctctg caaggctggta ctgtgttta caatcatctt gcccacatctt ggtaccctta  
1921 tatcactctt ttttcaag aatacaatac gtgttgttta actatagtca ccatgtgtt  
1981 caagatccctt gaacttatgc ctccctaactt aaattttgtt ttcttgaca catctgccc  
2041 gtccctctcc tcccagccca tggtaaccag catttgactc ttacttgta taagggcagc  
2101 ttttataggt tccacatgtt agtggatca tgcaactgtttt gtctttctgtt gcctggctta  
2161 ttctactcag cataatgtgc accgggttca cccatgtttt cataaatgac aagatttcct  
2221 ctttaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaa

Figure 12

**15/20**

3901 gcatgttgtt tcatacggttct ccttcattta atgcccattat tcataaaaggg tttgatgagc  
3961 gacatgcata cataggagga atgttgggg ccgggattta ttttgcgtaa aactcctcaa  
4021 aaagcaacca atatgtttat ggaattggag gaggaacagg ctgccctaca cacaaggaca  
4081 ggcatgtcta tatatgtcac agacaaatgc tcttcgttag agtgaccctt gggaaatcct  
4141 ttctgcagtt tagcaccatg aaaatggccc acgcgcctcc agggcaccac tcagtcatcg  
4201 gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctacaga ggagaacagg  
4261 catacccaga gtatcttatac acttaccaga tcataaagcc agaagccct tcggcagaccg  
4321 caacagccgc agagcagaag acctagtcaa tgcctgctgg tgaaggccag atcagatttc  
4381 aacctgggac tggattacag aggattgttt ctaataacaa catcaatatt ctagaagtcc  
4441 ctgacagcct agaaataaagc tggttgtctt ctataaagca ttgctatagt g

Figure 13

1 cgcggccct cgctagccga aacctgccc gccgggtccc ggccactgcg cacgcgcggg  
61 acgacgtcac gtgcgtccc ggggctggac ggagctggca ggaggggcct tgccagcttc  
121 cggccgcgc tcgttgcagg acccggacgg cggattcgcg ctggctccgc cgccgcggg  
181 cagccgggg gcagggagcc cagcgagggg cgcgcgtggg cgcggccatg ggactgcgc  
241 ggatccgtg acagcaggga gccaagcgc ccgggccctg agcgctt ctccgggggg  
301 cctcgccctc ctgctcgccg ggccggggt cctgtccgg ttgtcgcc tttgtcgcc  
361 tgtggcgccg gccaggatca tgcgggtcg cgcgtgcgc ggccggggag cggcgtgcgc  
421 gagcgcgcgc gccgaggccg tggagccgc cgcccgagag ctgtcgagg cgtgcgc  
481 cggggacgtg gaacgagtca agaggctggt gacgcctgag aaggtgaaca gccgc  
541 ggcgggcagg aaatccaccc cgctgcactt cgccgcagg tttggcgaa aagacgtag  
601 tgaatatttgc ttcagaatgt gtgcataatgt ccaagcacgt gatgtgggg gccttattcc  
661 tcttcataat gcatgttgc tttgtcgatgc tgaagtagtca aatctccctt tgccatgc  
721 tgcagacccc aatgctcgag ataattggaa ttatactcct ctccatgaag ctgcattaa  
781 aggaaagatt gatgttgca ttgtcgatgc acagcatgaa gctgagccaa ccatccgaaa  
841 tacagatgga aggacagcat tggatitgc agatccatct gccaaggcag tgcitactgg  
901 tgaatataag aaagatgaaac tcttagaaag tgccaggagt ggcaatgaa aaaaaatgat  
961 ggctctactc acaccattaa atgtcaactg ccacgcaggat gatggcagaa atcaactcc  
1021 attacatttgc cagcaggat ataacagatgaa aagattgtc cagctgttac tgcaacatgg  
1081 agctgtatgc catgttaaag ataaaggatgtc tctggatcca ttacacaatg cctgttcta  
1141 tggcattat'gaagtaactg aacttttgtt caagcatggt gcctgtgtaa atgcaatgga  
1201 cttgtggcaa ttcatcctc ttcatgaggc agcttctaa aacagggtt aagtatgtt  
1261 tcttccttca agttatggc cagacccaaactgtcaat tgcacaataa aagtgctat  
1321 agacttggct cccacaccac agttaaaaga aagattatgc tatgaattt aaggccactc  
1381 gttgctgcaa gtcacgcgg aagctgtatgt tactcgaatc aaaaaacatc tctctctgga  
1441 aatggtaat ttcaagcatc ctcaaacaca tggaaacagca ttgcattgtc ctgcgtcatc  
1501 tccatatccc aaaagaaagc aaatatgtca actgttgcata agaaaaaggag caaacatcaa  
1561 tggaaagact aaagaatttgc tgactcctct gcacgtggca tctgagaaag ctatcatgaa  
1621 tggatgttgc aatgtggatgc aacatgaaaggc aaaggtaat gctctggata atctggatgc  
1681 gacttcctca cacagagctg catattgtgg tcatctacaa acctgcgc tctctctgag  
1741 ctatgggtgt gatccataaca ttatccct tcagggctt actgttac agatggaaa  
1801 tggaaatgtc cagcaactcc tccaaaggagg tatctcattt ggttatttc aggcagac  
1861 acaatttgcgaa gaagctgcaaa aggctggaga tgcgttactt gtaaaaaaac tggactgt  
1921 tcagactgtc aactgcagag acattgtggc ggcgttgc acaccacttc attttgc  
1981 tgggtataac agatgtccg tggatgttgcata tgcgttactt gatgtcatgc  
2041 taaagataaa ggaggccctt taccttgca caatgtatgt tcttgcattt attatgt  
2101 tgcagaactt ctgtttaaac atggaggcgt agttaatgtc gctgatttat gggaaatttac  
2161 acctttacat gaagcagcag caaaaggaaa atatgaaatttgc acaccatc tgc  
2221 tggatgttgc aacttacaaaaaaa aaaacaggaa tggaaatactt ccttgcattt tggatgtt  
2281 tggatgttgc aacttacaaaaaaa aaaacaggaa tggaaatactt ccttgcattt tggatgtt  
2341 gaagggtgtt ttagccagag tggatgttgc gtcatttc gataatgtaa atggccgc  
2401 tacccaaaggc agacattcaa caccttaca tttagcgtt ggttataata atttgt  
2461 tgcagactgtt tggatgttgc acggaggctg tggatgttgc caagacaaaagg gaggactt  
2521 tccatcatttacat aatgcagcat ctacggca tggatgttgc gtcatttc taataatgt  
2581 taatgttgc tggatgttgc acggaggctg tggatgttgc gtcatttc aacggcc  
2641 aaaggacga acacagctt tggatgttgc gtcatttc ggttataata atttgt  
2701 aaatcaggaa ggacaaacac cttagattt agtgcgttgc gatgtatgtca ggc  
2761 gacacgcgc atgcgcgc tggatgttgc tgcatttc aacggcc tggatgttgc

17/20

2821 tgtgagaagc ccaggagcca ctgcagatgc tctctttca ggtccatcta gcccatcaag  
2881 ccttctgcga gccagcagtc ttgacaactt atctgggagt tttcagaac tgtcttcagt  
2941 agtttgtca agtggAACAG agggtgcTTc cagTTGGAG aaaaaggagg ttccaggagt  
3001 agattttAGC ataactcaat tcgtAAGGAA tcttgactt gagcacctaA tggatataatt  
3061 tgagagagaa cagatcactt tggatgtatt agttgagatg gggcacaagg agctgaagga  
3121 gattggaaATC aatgcTTATG gacataggca caaactaatt aaaggagtgc agagacttat  
3181 ctccggacaa caaggTCta acccatattt aacttGAAC acctctggta gtggacaat  
3241 tcttagat ctgtctcTG atgataaaga gtttcAGTCT gtggagGAAG agatgcaaaG  
3301 tacagtTCga gagcacAGAG atggaggTCa tgcaggTggA atctcaaca gatacaaat  
3361 tctcaagattt cagaaggTTT gtaacaAGAA actatggAA agatacACTC accggagaaaa  
3421 agaaggTTCT gaagAAAACC acaaccatGC caatgaacGA atgcTATTc atgggtCTCC  
3481 ttttgtaat gcaattatCC acaaaggCTT tgatgaaAGG catgcTACA taggtggat  
3541 gtttggagCT ggcatttatt ttgctgaaaaa ctcttccaaa agcaatcaat atgtatatgg  
3601 aattggagGA ggtactggGT gtccAGTCA caaAGACAGA tcttggTACA tttGCCACAG  
3661 gcagCTGTC tttGCCGGG taacCTTGGG aaagtCTTC ctgcAGTCA gtgcaatgaa  
3721 aatggcacat tctcCTCCAG gtcATCactC agtcaCTGtT aggcccAGTg taaatggcCT  
3781 agcattAGCT gaatATGTTA ttacAGAGG agaacAGGtT tatcCTGAGT attaattAC  
3841 ttaccAGATT atgaggcCTG aaggTAgttGtT cGatggataa atagttaTTT taagaaACTA  
3901 attccACTGA acctaAAAATC atcaAAAGCAG cagtggCCTC tacgttttac tcctttGCTG  
3961 aaaaaaaaaATC atctGCCCA caggCCTGTG gcaAAAGGAT AAAAATGTGA acgaAGTTA  
4021 acattCTGAC ttgataAAAGC ttaataATG tacagtGTT tctaaatatt tcctgtTTT  
4081 tcagcacTTT aacAGATGCC attccAGGTT aaactggGTT gtctgtACTA aattataAAAC  
4141 agagttAACT tgaacCTTTT atatGTTATG cattGATTCT aacAAACTGT aatGCCCTCA  
4201 acagaACTAA ttTtactAAT acaataCTGT gttctttAAA acacAGCATT tacACTGAAT  
4261 acaatttCAT ttgtAAAAct gtaaATAAGA gctttgtac tagcccAGTA tttatttaca  
4321 ttgcttGTA atataAAATCT gttttagAAC tgcaGCGGTT tacaAAATTt ttcatatGT  
4381 attgttCATC tataCTtCAT CTTACATCGT catgattGAG tgatcttac atttgattCC  
4441 agaggCTATG ttcaGTTGTT agttggAAAG gattgagTTA tcagattAA ttGCCGATG  
4501 ggagcTTA tctgtcatta gaaatCTTC tcatttaAGA acttAtGAAT atgctGAAGA  
4561 tttaatttGT gatacCTTTG tatgtatGAG acacattCCA aagagCTCTA actatGATAG  
4621 gtcctgaita ctaaAGAAGC ttctttACTG gcctcaattt ctAgcttCA tGttggaaaa  
4681 ttTCTGAG tccttcTG AAAATTAGAG caaaAGTGCtC ctgttttta gagaaACTAA  
4741 atcttgctgt tgaacaATTt ttgtttCTT ttcatggAAC ataagttagGA tGttaacATT  
4801 tccaggGTGG gaaggtaat CCTAAATCAT ttccCAATCT attctaATTt CCTAAATCT  
4861 aaaggggAAA aaaaaaaaaATCA caaaCAGGAC tgggtAGTT ttatCCTAA gtatTTT  
4921 tcctgttCTT ttacttGCTG tatttAtAGC caaCTtatac atcatggta  
4981 aacttaACCC agaactataa aatgttagttG ttTCAGtCCC CTTCAGGCT CTCGAATGGG  
5041 caagtgcAGT gaaacAGGTG ttccCTGTC ctgggtttTC tctccatGAT gttatGCCA  
5101 attggAAATA tgctgtcAGT ttgtgcACCA tatggTGACC acgcctgtc tcagttggc  
5161 agctatAGAA ggaatGCTG tcccataAAA tgccatCCt ATTtctaATA taacACTtT  
5221 ttccAGGAAG catGCTTAAG catCTGTtA cagAGACATA catCCATTat ggcttggCAA  
5281 tctctttat ttgttgactC tagCTCCtT caaAGTCAG gaaAGATCTT tactcaCTTA  
5341 atgaggACAT tccccatCAC tGTCtGtAcc agttcacCTT tatttACGT ttattcAGT  
5401 ctgtAAATTa actggCCtT tGcAGTAACT tGtAcATAA gTGCTAGAAA atcatgttCC  
5461 ttgcctGAG taaggtaa tcaAGAGTAAG tgcatttCTG gagttGTTtC tGtGAGtGA  
5521 attatGATCA ttatttAAGA agtcaaATCC tGATCTGAA tGtGTTtTA tacAGCTCTC  
5581 taataAttAC aataATCCGA aAGTCATTc ttGGAACACA AGTGGAGTAT gccaAAATTt  
5641 atatGAATT ttcAGATTt CTAAGCTtC AGTTtATAA attAGAAGAT AATGAGAGAA  
5701 ttaatgggGT ttatatttAC attatCTCTC aactatGtAG cccatattAC tcaccCTATG  
5761 agtGAATCTG gaattGCTT tcatgtgaaa tcattGTTGtT ctatGAGTT acaataCTG

18/20

5821 aaactgtgtt attttatcta aaccattgct taatgagtgt gttttccat gaatgaatat  
5881 accgtggttc atatgttagc atggcagcat ttcagatag cttttgttt gttgggaagt  
5941 tggggtttg gggggagggg gaggatttgt acgttgcata gaatagcata cttataatg  
6001 atgggaatgc ttttcttt gtttggat tttttttt gaagtggaaat ttaactttt  
6061 gtgccagtag tactattata cccatctca gtgtcttact tgtactgtat caaattccat  
6121 accctcattt aattctaat aaaactgttc acttgtaaaa aaaaaaaaaa aaaaaaaaaa  
6181 aaaaaaaaaa

Figure 14

1 cgcccccccc gccccggggg caggaaagc ctaaattacg gaattaccgc gagcaaggag  
61 cgcggaatcg gggagcgtcc ggagcttagct ggatcctcta gcaggatgg tgatggaaat  
121 ctttgc当地 ttttgc当地 agacttgc当地 ctc当地 gagc当地  
181 gctacaact gacattaagg aaaatggcgg aaagtttcc ttgc当地 atc当地  
241 cacacatata atcttagata atgc当地 tctgagtc当地 taccaactga attctatcca  
301 aaagaaccac gttcatattg caaaccaga ttttatatgg aaatctatca gagaaaagag  
361 actcttggat gtaaagaatt atgatcccta taagccctg gacatcacac cacccctg  
421 tc当地 aggac agc当地 tctg aagtggaaac agaaggctta tgccc当地 gtc当地  
481 ggaggaagac actgtggaaac tcactgagg ttgtatgc当地 aatgttggaa ttccatct  
541 tcc当地 agat ttgc当地 caaaatataa cacccggag aaagtggaa tggaggagg  
601 cc当地 agagct gtgggtgg agcttgc当地 ttc当地 cggac tccaggact gtc当地  
661 gatatcccta cactccctc tggatgatgg catggagact agaagacact ttgc当地  
721 gaaaacctct gaagatgcaa gt当地 aactt tgaaaattac attgaagaaac tgaagaaaca  
781 aggattctct ctaagagaaac atttc当地 accc tgaagcaacc caattagcat ct当地  
841 gcaagcattt ctttggagg aagtcatgaa ttcaagcact ct当地 gccaag aggtgagc  
901 tttagtagag atgatgggg cagaggccct gggccacctg gaacacatgc ttctca  
961 agtgaacagg attgc当地 acgatgtgag caaggcagag gggattctcc ttctag  
1021 ggc当地 agactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagat  
1081 cagactgata cctc当地 caaaag gcacaatgcc caaagaactg aacctggac tattgg  
1141 gaaagcagac ct当地 cccagc taataagaga catggtaat gtc当地  
1201 caaacc当地 ac cc当地 accatccc tggcc当地 aataa cccgactt  
1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag ttgc当地 atcat  
1321 taagagcccc gtggatgtct tgca  
1381 gtggatgtct tgca  
1441 gttttgagc aaacttggta atgtgaggcc ct当地 ttgtgc当地  
1501 aagaacagac gtc当地 ggaaacc ttggagtg  
1561 tatcaagtg  
1621 agccctcgga aagtgtatgg  
1681 aggctacgac agtgc当地  
1741 tgatgaattt  
1801 catgc当地  
1861 cagac  
1921 ttcc  
1981 tg  
2041 caca  
2101 c  
2161 ga  
2221 gat  
2281 ta  
2341 ct  
2401 tc  
2461 gact  
2521 gaa  
2581 c  
2641 tga  
2701 tgc

20/20

2761 ttccatggag ggtgtacat tcttgcagc caagcaaatc accttgcatt cgctgtccct  
2821 ggtgggttag aagcagaaaag taaatattat ccagtgcgc acaggatata aggagtttatt  
2881 ttcttatctt aagcatatca caagcaatac cacggcagca gagttcatca tgctgtccac  
2941 acctaccatg gggAACACAG acttctggaa aacactccga tatcttagct tattgtaccc  
3001 tgctcgaggg tcacggaca tcctcctggt gtctgatggg caccctcagg atgagagcct  
3061 gacattacag ctcgtgaaga ggagccgccc gcacaccagg ttatcgccgcgatcg  
3121 ttctcacagca aatcgtcactg tcttaaggat ttgtcccaag tgggtgccc gagtttga  
3181 atattttat gcaaataatcca agcatagttt gagaaaaacag atagaagacc aaatgaccag  
3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc  
3301 gccccgaggccc ctgcaggccc cagccccaggt gccatccttg ttgcataatg atcgactcct  
3361 tgtctatgat ttcatttcactgcacaca agcaactctg tgtgcactaa ttcaagagaa  
3421 agaattttgtt acaatgggtt cgactactga gcttcagaag acaactggaa ctatgatcca  
3481 caagctggca gcccgagctc taatcagaga ttatcagaat ggcattctc acgaaaaatga  
3541 aaccagtcat gagatgaaaaa aacaaacctt gaaatctctg attattaaac tcagtaaaga  
3601 aaactctctc ataacacaat ttacaagctt tggtcgattt gagaaaaaggg atgagaatga  
3661 gtcgcctttt cctgtatattt caaaaatttt tgaacttattt gccaaagaag atgttagactt  
3721 cctgccttac atgagctggc agggggagcc ccaagaagcc gtcaggaacc agtctttt  
3781 agcatccttct gaggccatg aattacgtt atccaaacga aaacatagga aaattccatt  
3841 ttccaaaaga aaaatggat taatcagcc agaagtttct gaagatttt aagaggatgg  
3901 cttaggtgtt ctaccagctt tcacatcaaa ttggaaacgt ggaggtgtgg aaaagctatt  
3961 ggatttaagt tggacagagt catgtaaacc aacagcaact gaaccactat ttaagaaaat  
4021 cagtcatgg gaaacatcta cttctagttt tttccattt ttggctccgg ccgttggc  
4081 ctatcttacc ccgactaccc ggctcacag tcctgcctcc ttgtctttt cctcatatcg  
4141 tcaggtatgtt agttcggtt cagctgcctcc tcccagacag ttgtatgcatttgc  
4201 ccaaggccct gtgcctggca ctgtgctga ctggatccca cagtcggcgt ctgtccac  
4261 aggacctccc cagaacccac ctctgcacc ctatgtggc attttttt cagggagctc  
4321 attaagctct gcacagtctg ctccactgca acatctggaa ggcttacta ccaggccctc  
4381 tgctggcacc ttccctgagc tggattctcc ccagctcat ttctcttc ctacagaccc  
4441 tgatcccatc agagggtttt ggtcttatca tccctctgt tactcttctt ttcatatca  
4501 acctccgca gccttttga ctgccaacct taggctgcca atggcctctg ctttacctga  
4561 ggcttttgc agtcagtccc ggactacccc agtagatctc tgcattttt aagaatcgt  
4621 aggcagtctc gaaggaagic gatgtccctgtt ctggctttt caaagtctg acacagaaaag  
4681 tgatgagctt tcagaagtac ttcaagacag ctgcattttt caaataaaatgt gtgatcacaaa  
4741 agatgacagt atccctgtt ttctggattt aaaagaagag gatgaaatag tggcacaca  
4801 acactggcag gatgtgtgc ctggacaga actcctcattt ctacagacag aggatggctt  
4861 ctggaaactt acaccagaac tggacttat attaaatctt aatacaatg gttgcacag  
4921 ctttctttaaa caaaaaggca ttcaatctt aggtgtaaaaa ggaagagaat gtcctctgg  
4981 cctaattgcc acaatgctgg tactacagtt tattcgacc aggttggaaa aagaggaaat  
5041 agtgttcaaa tcactgatga aaatggatga cccttcttattt tccaggaata ttccctggc  
5101 ttgtgaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc  
5161 tatctgccc cggctgttac tggggaaacga ctggactctt gccaaccatc agttgtgg  
5221 actccagccc ataagcactg tgccttctt tcatagatgc ctccattaca gtcaaggctt  
5281 agtcaaatga aactgaattt taaactttt gcatgctctt atgtagaaaaa taatcaatgt  
5341 ataataatgata attataatga aacttcattt aggttctt cagtgatgc attactgtct  
5401 ttaaaaatattttaa agtggaaagaa gaattactttt aatcaactaa caagcaataa taaaatgaaa  
5461 cttaaaataa aaaaaaaaaa aaaaaaaaaaaa

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/003235

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12N15/11 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search, CHEM ABS Data, EMBASE, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | MASSUDA EDMOND ET AL: "GPI 6150, a PARP inhibitor, down-regulates metastasis associated S100A4 (Mts1) and suppresses invasion of breast cancer cells in vitro." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07), pages 867-868, XP001181719 & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003 ISSN: 0197-016X abstract<br>----- | 1-5,<br>11-32         |
| X          | WO 02/12239 A (BOLKENIUS FRANK ; SANOFI SYNTHELABO (FR); BARTH FRANCIS (FR); BICHON D) 14 February 2002 (2002-02-14) claims<br>-----  | 1-5,<br>11-32         |
|            |   | -/-                   |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

|  |  |
|--|--|
| Date of the actual completion of the International search  | Date of mailing of the international search report |
| 18 November 2004   | 01/12/2004   |
| Name and mailing address of the ISA<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax: (+31-70) 340-3016 | Authorized officer<br><br>Didelon, F               |

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/003235

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |  |                       |
|--|--|-----------------------|
| Category °   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
| X  | WO 95/24379 A (CALVERT ALAN HILARY ; CANCER RES CAMPAIGN TECH (GB); CURTIN NICOLA JAN) 14 September 1995 (1995-09-14)<br>claims<br>-----   | 1-5,<br>11-32         |
| X  | WELTIN D ET AL: "EFFECT OF 6(5H)-PHENANTHRIDINONE, AN INHIBITOR OF POLY(ADP-RIBOS) POLYMERASE, ON CULTURED TUMOR CELLS"<br>ONCOLOGY RESEARCH, PERGAMON PRESS, NEW YORK, NY, US,<br>vol. 6, no. 9, 1994, pages 399-403,<br>XP008003298<br>ISSN: 0965-0407<br>abstract<br>-----    | 1-5,<br>11-32         |
| P, Y   | SCHULTZ NIKLAS ET AL: "Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination."<br>NUCLEIC ACIDS RESEARCH,<br>vol. 31, no. 17,<br>1 September 2003 (2003-09-01), pages 4959-4964, XP002305998<br>ISSN: 0305-1048<br>the whole document<br>----- | 1-32                  |
| Y  | LARMINAT FLORENCE ET AL: "Deficiency in BRCA2 leads to increase in non-conservative homologous recombination"<br>ONCOGENE,<br>vol. 21, no. 33,<br>1 August 2002 (2002-08-01), pages 5188-5192, XP002305999<br>ISSN: 0950-9232<br>the whole document<br>-----                     | 1-32                  |
| A  | SHALL SYDNEY ET AL: "Poly (ADP-ribose) polymerase-1: What have we learned from the deficient mouse model?"<br>MUTATION RESEARCH,<br>vol. 460, no. 1,<br>30 June 2000 (2000-06-30), pages 1-15,<br>XP002306000<br>ISSN: 0027-5107<br>the whole document<br>-----                  | 1-32                  |
| A  | DATABASE EMBL 23 March 2001 (2001-03-23), STRAUSBERG, R.:<br>XP002306001<br>retrieved from EBI<br>Database accession no. BG483078<br>abstract<br>-----   | 8                     |
|  |  | -/-                   |

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/003235

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| A          | ELBASHIR SAYDA M ET AL: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells"<br>NATURE, MACMILLAN JOURNALS LTD. LONDON,<br>GB,<br>vol. 411, no. 6836,<br>24 May 2001 (2001-05-24), pages 494-498,<br>XP002206451<br>ISSN: 0028-0836<br>the whole document<br>----- | 1,6-10                |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB2004/003235

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. type of material
    - a sequence listing
    - table(s) related to the sequence listing
  - b. format of material
    - in written format
    - in computer readable form
  - c. time of filing/furnishing
    - contained in the international application as filed
    - filed together with the international application in computer readable form
    - furnished subsequently to this Authority for the purpose of search
2.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/003235

| Patent document cited in search report | Publication date |  | Patent family member(s) |  | Publication date |
|--|------------------|--|-------------------------|--|------------------|
| WO 0212239                             | A 14-02-2002     |  | FR 2812878 A1           |  | 15-02-2002       |
|  |                  |  | FR 2816619 A1           |  | 17-05-2002       |
|  |                  |  | AU 8226701 A            |  | 18-02-2002       |
|  |                  |  | BG 107460 A             |  | 30-09-2003       |
|  |                  |  | BR 0113046 A            |  | 01-07-2003       |
|  |                  |  | CA 2412368 A1           |  | 14-02-2002       |
|  |                  |  | CN 1446218 T            |  | 01-10-2003       |
|  |                  |  | CZ 20030354 A3          |  | 14-05-2003       |
|  |                  |  | EP 1309594 A1           |  | 14-05-2003       |
|  |                  |  | WO 0212239 A1           |  | 14-02-2002       |
|  |                  |  | HU 0301514 A2           |  | 29-09-2003       |
|  |                  |  | JP 2004505975 T         |  | 26-02-2004       |
|  |                  |  | NO 20030596 A           |  | 01-04-2003       |
|  |                  |  | SK 1582003 A3           |  | 05-08-2003       |
|  |                  |  | US 2003203893 A1        |  | 30-10-2003       |
|  |                  |  | ZA 200300479 A          |  | 05-02-2004       |
| WO 9524379                             | A 14-09-1995     |  | AT 184271 T             |  | 15-09-1999       |
|  |                  |  | AT 210651 T             |  | 15-12-2001       |
|  |                  |  | AT 231494 T             |  | 15-02-2003       |
|  |                  |  | AU 693167 B2            |  | 25-06-1998       |
|  |                  |  | AU 1856595 A            |  | 25-09-1995       |
|  |                  |  | CA 2184747 A1           |  | 14-09-1995       |
|  |                  |  | CA 2350941 A1           |  | 14-09-1995       |
|  |                  |  | CA 2352592 A1           |  | 14-09-1995       |
|  |                  |  | CN 1143358 A ,B         |  | 19-02-1997       |
|  |                  |  | DE 69512036 D1          |  | 14-10-1999       |
|  |                  |  | DE 69512036 T2          |  | 30-12-1999       |
|  |                  |  | DE 69524641 D1          |  | 24-01-2002       |
|  |                  |  | DE 69524641 T2          |  | 14-08-2002       |
|  |                  |  | DE 69529482 D1          |  | 27-02-2003       |
|  |                  |  | DE 69529482 T2          |  | 12-06-2003       |
|  |                  |  | DK 749415 T3            |  | 20-03-2000       |
|  |                  |  | DK 879820 T3            |  | 02-04-2002       |
|  |                  |  | EP 0749415 A1           |  | 27-12-1996       |
|  |                  |  | EP 0879820 A1           |  | 25-11-1998       |
|  |                  |  | EP 0897915 A1           |  | 24-02-1999       |
|  |                  |  | ES 2135707 T3           |  | 01-11-1999       |
|  |                  |  | ES 2169472 T3           |  | 01-07-2002       |
|  |                  |  | WO 9524379 A1           |  | 14-09-1995       |
|  |                  |  | GR 3031886 T3           |  | 29-02-2000       |
|  |                  |  | JP 9510704 T            |  | 28-10-1997       |
|  |                  |  | PT 879820 T             |  | 28-06-2002       |
|  |                  |  | US 6015827 A            |  | 18-01-2000       |
|  |                  |  | US 6316455 B1           |  | 13-11-2001       |
|  |                  |  | US 5756510 A            |  | 26-05-1998       |